Sanofi, a global biopharmaceutical company, offered to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products, for $358m. Companies entered into an agreement pursuant to which Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to acquire the entire share capital of Kiadis. “We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches,” John Reed, Sanofi Global Head of Research & Development. On February 12, 2021: Sanofi offered to acquire Kiadis for $373m.